CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome

Last updated: March 24, 2017
Sponsor: xuhuijuan
Overall Status: Active - Recruiting

Phase

N/A

Condition

Post-menopausal Osteopenia

Osteoporosis

Treatment

N/A

Clinical Study ID

NCT02981732
81674007
  • Ages 46-75
  • Female
  • Accepts Healthy Volunteers

Study Summary

For nearly 112 million patients with osteoporosis in China, it is of great significance for preventing and treating by clearly understanding the molecular mechanism of kidney deficiency. Thus, the research group has demonstrated in the earlier research that CLCF1 is an associated gene that can regulate JAK2/STAT3 signal pathway and impact bone metabolism for kidney yin deficiency of postmenopausal osteoporosis (PMOP). To make clear understanding of the direct-acting mechanism of CLCF1 for bone metabolism, this study intends to: ①observe impacts of low expression of CLCF1 upon immunities in mice and OPG/RANKL/RANK signal system using the technology of adenovirus associated virus. ②explore impacts of over-expression and silencing of CLCF1 on B lymphocytes by culcuturing the cells together with osteoblasts. ③ analyze the impacts of treating kidney yin deficiency of PMOP by Liuwei Dihuang pill upon immunities and OPG/RANKL/RANK system, and discuss the mechanism of regulating bone metabolism by CLCF1 by OPG/RANKL/RANK system via the bridge between immune system and bone metabolism, so as to demonstrate if the hypothesis of this study that "the molecular osteoimmunological mechanism of kidney yin deficiency of postmenopausal osteoporosis (PMOP) is possibly closely related to the impacts of CLCF1 regulation of OPG/RANKL/RANK signal system on bone metabolism" is right or not.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients were included if they were female Han Chinese patients who had undergonenatural menopause at least 2 years prior and

  • met the diagnostic criteria for osteoporosis according to the "clinical practiceguidelines of traditional medicine for primary osteoporosis"

  • met the CM diagnostic criteria according to "Syndrome Differentiation in ModernResearch of Traditional Chinese Medicine"

  • provided informed consent, which was approved by the Fujian Academy ofTraditional Chinese Medicine Clinical Research Ethics Committee

Exclusion

Exclusion Criteria:

  • patients who did not meet the diagnostic criteria for osteoporosis or CM standards

  • patients with rheumatoid arthritis, diabetes, secondary osteoporosis due tohyperthyroidism, and severe cardiovascular or cerebrovascular diseases

  • patients with abnormal liver and/or Shen function test results

  • patients with osteoporosis who had received treatment with CM within the last month,hormone replacement therapy and calcitonin within the past three months, orbisphosphonates for 15 consecutive days within the past 6 months.

Study Design

Total Participants: 60
Study Start date:
October 01, 2016
Estimated Completion Date:
December 31, 2020

Connect with a study center

  • Fujian Academy of Trational Chiness Medicine

    Fuzhou, Fujian 350003
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.